Primary Care

Pfizer's goal is to continue to lead in Primary Care through effective and efficient delivery of our portfolio today, and continued innovation to meet customer and patient needs as healthcare systems transform around the world. With a heritage of developing medicines that improve health, Primary Care's broad portfolio includes products such as: Eliquis, Viagra, Celebrex, Chantix/Champix, Lyrica and Pristiq. Our focus is on high-need disease areas such as Pain, Cardiovascular and Metabolic Disease, and Alzheimer's disease.

• See Contact List for Primary Care

Specialty Care

Pfizer's Specialty Care Business Unit features a successful portfolio of medicines, many of them market leaders, spanning 11 therapeutic areas and a rich pipeline of promising new products. Our multinational business is committed to the eradication, remission and relief of serious diseases. We are leaders in vaccines and biologics, two of the most important areas of innovation and growth in the industry, and have a leading presence in inflammation, infectious disease, and hemophilia.

• See Contact List for Specialty Care

Oncology

Pfizer Oncology is striving to cure or control cancer with breakthrough medicines. Compounds under evaluation are across four scientific platforms — anti-angiogenesis, signal transduction, cell cycle, and metabolism — and multiple tumor types. Guided by the principles of precision medicine and working collaboratively with academic institutions, individual researchers, cooperative research groups, governments, licensing partners, and other partners, we aim to deliver the right drug at the right time for each patient.

Oncology is a core area of research focus for Pfizer. Our Oncology Research Unit and Business Unit work in seamless partnership, with a mutual commitment to delivering highly innovative and commercially viable cancer therapies. In order to fulfill this commitment, we are continuously managing and refining our dynamic portfolio, which includes deciding which compounds to develop internally and which may be candidates for continued development through partnerships. At the same time, we are looking to complement our internal portfolio with compounds in early clinical development, those that have achieved proof of concept in randomized controlled multicenter phase 2 trials and phase 3 programs. We are seeking greater depth and breadth in key disease areas in our late-stage portfolio — renal cell carcinoma, lung cancer, hematologic malignancies, and breast cancer — while also looking to develop breakthrough medicines in other areas of unmet need. In addition, our Oncology Research Unit is focused in established areas such as cell signaling, and emerging areas of cancer biology, including tumor metabolism, epigenetics and antibody-drug conjugates (ADCs), a highly promising therapeutic modality that provides targeted delivery of an antibody drug linked to chemotherapy.

• See Contact List for Oncology
• Link to R&D Oncology

Emerging Markets

The Emerging Markets Business Unit is committed to meeting the diverse medical needs of patients in emerging markets in an innovative, socially responsible and commercially viable manner. We welcome the opportunity to develop innovative partnerships with companies from all industries to reach patients we have never reached before, and provide affordable and sustainable medicines and services.

• See Contact List for Emerging Markets

Established Products

The Established Products Business Unit has more than 600 branded and generic products in its portfolio, including many familiar brands such as Lipitor, Norvasc, Zoloft, Effexor and Zithromax. Our mission is to provide patients and payers with affordable medicines, characterized by Pfizer's reputation for quality, safety and innovation. Established products span a range of therapeutic areas, including solid oral dose medications, as well as distinct "niche" products such as sterile injectables and biosimilars.

• See Contact List for Established Products